3,436 reports of this reaction
2.8% of all TOPIRAMATE SPINKLE reports
#3 most reported adverse reaction
HEADACHE is the #3 most commonly reported adverse reaction for TOPIRAMATE SPINKLE, manufactured by Advagen Pharma Ltd. There are 3,436 FDA adverse event reports linking TOPIRAMATE SPINKLE to HEADACHE. This represents approximately 2.8% of all 124,712 adverse event reports for this drug.
TOPIRAMATE SPINKLE has an overall safety score of 85 out of 100. Patients taking TOPIRAMATE SPINKLE who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for TOPIRAMATE SPINKLE, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for TOPIRAMATE SPINKLE:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 3,436 FDA reports for TOPIRAMATE SPINKLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 2.8% of all adverse event reports for TOPIRAMATE SPINKLE, making it one of the most commonly reported side effect.
If you experience headache while taking TOPIRAMATE SPINKLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.